ArticleMolecular and cellular biology1999
Mapping of a serine-rich domain essential for the transcriptional, antiapoptotic, and transforming activities of the v-Rel oncoprotein.
Article in Molecular and cellular biology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Structural properties of the HNF-1A transactivation domain.Frontiers in molecular biosciences · 2023Article
- Neuroprotective effects of DHA-derived peroxidation product 4(RS)-4-F4t-neuroprostane on microglia.Free radical biology & medicine · 2022Article
- Atoh8 in Development and Disease.Biology · 2022Review
- An essential domain of an early-diverged RNA polymerase II functions to accurately decode a primitive chromatin landscape.Nucleic acids research · 2017Article
- Article
- Article
- Stimulation of c-Rel transcriptional activity by PKA catalytic subunit beta.Journal of molecular medicine (Berlin, Germany) · 2004Article
- Article
- Article
- Mutations in the v-Rel transactivation domain indicate altered phosphorylation and identify a subset of NF-kappaB-regulated cell death inhibitors important for v-Rel transforming activity.Molecular and cellular biology · 2003Article
- NF-kappaB in pancreatic cancer.International journal of gastrointestinal cancer · 2003Review
- BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19).The American journal of pathology · 2001Article
- Article
- cRel-TD kinase: a serine/threonine kinase binding in vivo and in vitro c-Rel and phosphorylating its transactivation domain.Oncogene · 2000Article
- The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L).Molecular and cellular biology · 2000Article
- Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein.Oncogene · 2000Article
- Aberrant rel/nfkb genes and activity in human cancer.Oncogene · 1999Review
- Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel.Oncogene · 1999Review
- LIM domain-containing protein trip6 can act as a coactivator for the v-Rel transcription factor.Gene expression · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The v-Rel oncoprotein belongs to the Rel/NF-kappaB family of transcription factors and induces aggressive lymphomas in chickens and transgenic mice. Current models for cell transformation by v-Rel invoke the combined activation of gene expression and the dominant inhibition of transcription mediated by its cellular homologs. Here, we mapped a serine-rich transactivation domain in the C terminus of v-Rel that is necessary for its biological activity. Specific serine-to-alanine substitutions within this region impaired the transcriptional activity of v-Rel, whereas a double mutant abolished its function. In contrast, substitutions with phosphomimetic aspartate residues led to a complete recovery of the transcriptional potential. The transforming activity of v-Rel mutants correlated with their ability to inhibit programmed cell death. The transforming and antiapoptotic activities of v-Rel were abolished by defined Ser-to-Ala mutations and restored by most Ser-to-Asp substitutions. However, one Ser-to-Asp mutant showed wild-type transactivation ability but failed to block apoptosis and to transform cells. These results show that the transactivation function of v-Rel is necessary but not sufficient for cell transformation, adding an important dimension to the transformation model. It is possible that defined protein-protein interactions are also required to block apoptosis and transform cells. Since v-Rel is an acutely oncogenic member of the Rel/NF-kappaB family, our data raise the possibility that phosphorylation of its serine-rich transactivation domain may regulate its unique biological activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.